https://www.selleckchem.com/pr....oducts/buloxibutid.h
09 (0.73-1.63), 1.48 (1.00-2.18), and 1.94 (1.35-2.77) fold increased risk (95% CI) of primary outcome in less then 15, 15 to 29, and ≥30 pack-year smokers compared with never-smokers. The association of longer smoking duration with higher risk of CKD progression was evident particularly in patients with eGFR less then 45 ml/min/1.73 m2 and proteinuria ≥1.0 g/g. In contrast, the risk of adverse kidney outcome decreased with longer smoking-free periods among former-smokers. CONCLUSIONS These findings suggest potentially harmful effec
Мне нравится
Комментарий
Перепост
